Talent and Culture Our people are critical to delivering CSL’s promise to patients, donors and public health. We continue to invest in attracting, developing and retaining talent by strengthening leadership capability, building future-ready skills and cultivating a culture of performance, inclusion and accountability. These efforts help ensure CSL has the talent and organisational capability required to execute its strategy and sustain long-term growth. Support in times of change This financial year has seen significant transformational changes throughout the CSL enterprise globally. During this time of change CSL has made best efforts to support its employees affected by these changes, both directly and via third parties. This included providing additional forums for open and honest communication, training and resources to help manage and deal with change and access to external services to help employees maintain their health and wellbeing during the significant changes. Investing in future leaders CSL’s Manufacturing Site Heads, Plasma Centre Managers, Commercial General Managers, and Global Product Leaders (GPLs) play a critical role in driving the company’s success. Together, these groups have been identified as CSL’s key Leadership Cohorts. This year, CSL launched a new initiative to invest in 375 leaders across these critical roles. The program provides tailored resources, development opportunities, and support to help leaders meet the specific accountabilities and challenges of their positions. Developed in partnership with business leaders and informed by external research, a Success Profile has been created for each cohort. These profiles clearly define the expectations, capabilities, and behaviours required for success in each role. The Success Profiles create value in three key ways: enabling stronger hiring decisions, supporting stronger performance, and building a stronger future by developing a leadership pipeline that is equipped to drive CSL’s long-term growth. Case Study – Phase 3 clinical trial activities to improve participation and accessibility CSL300_2301 (NCT05485961) is a CSL Phase 2b/3 clinical trial evaluating clazakizumab in adults with end-stage kidney disease (ESKD) receiving dialysis. The study is investigating if treatment can reduce heart attacks and cardiovascular deaths in patients with ongoing inflammation and either cardiovascular disease or diabetes. To reflect the people most affected by ESKD in the United States, CSL set enrolment goals based on national epidemiological data from the United States Renal Data System (USRDS). Targets included older adults, both males and females, and racial and ethnic groups that are disproportionately affected by ESKD. Patients were involved in the study design from an early stage. Patients recommended increasing education about ESKD, treatment options, and the study itself through dialysis centres and nephrologists. They also suggested offering home visits, reducing disruption by aligning study activities with routine dialysis appointments, and providing flexible options for completing patient-reported outcomes (PROs), including proxy support or completing questionnaires at home. Their feedback led to practical changes made by CSL to make participation easier, including aligning study activities with regular dialysis appointments, offering flexible options for completing questionnaires, and providing some assessments closer to home. CSL also partnered with patient organisations and community groups to raise awareness, improve education, and support retention and recruitment of participants. Study materials, including the informed consent form, were updated to make them easier to understand. To reduce the burden on participants, study visits and assessments are integrated into routine dialysis care wherever possible. This approach was strongly supported by participants in Phase 2b, who identified convenience and minimal disruption as key reasons for taking part in the study. Remote data collection options and support from dialysis networks also help improve access for patients in both urban and remote locations. Early results suggest that the study population is broadly representative of people affected by ESKD in the United States, including groups that have historically been underrepresented in clinical research. CSL believes that incorporating patient perspectives early in trial design and including representatives from the communities most affected will result in more patient-centric studies and ultimately better patient outcomes. Healthier Communities 32 Healthier World
RkJQdWJsaXNoZXIy MjE2NDg3